IL163777A0 - Kinase inhibitors - Google Patents

Kinase inhibitors

Info

Publication number
IL163777A0
IL163777A0 IL16377703A IL16377703A IL163777A0 IL 163777 A0 IL163777 A0 IL 163777A0 IL 16377703 A IL16377703 A IL 16377703A IL 16377703 A IL16377703 A IL 16377703A IL 163777 A0 IL163777 A0 IL 163777A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
formula
present
inhibitors
provides kinase
Prior art date
Application number
IL16377703A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL163777A0 publication Critical patent/IL163777A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16377703A 2002-03-08 2003-03-05 Kinase inhibitors IL163777A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36337502P 2002-03-08 2002-03-08
US36943302P 2002-04-02 2002-04-02
PCT/US2003/005052 WO2003076398A2 (en) 2002-03-08 2003-03-05 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
IL163777A0 true IL163777A0 (en) 2005-12-18

Family

ID=27807992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16377703A IL163777A0 (en) 2002-03-08 2003-03-05 Kinase inhibitors

Country Status (13)

Country Link
US (1) US7405305B2 (de)
EP (1) EP1487822B1 (de)
JP (1) JP2005530707A (de)
KR (1) KR20040091113A (de)
CN (1) CN1639152A (de)
AT (1) ATE368657T1 (de)
AU (1) AU2003217596A1 (de)
CA (1) CA2477984A1 (de)
DE (1) DE60315270T2 (de)
ES (1) ES2289274T3 (de)
IL (1) IL163777A0 (de)
MX (1) MXPA04008671A (de)
WO (1) WO2003076398A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
KR20060056377A (ko) * 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
MX2008000463A (es) * 2005-07-11 2008-03-11 Novartis Ag Derivados de indolil-maleimida.
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP1779851A1 (de) * 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Behandlung von Diabetes
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2410955T3 (es) 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2402547C1 (ru) * 2009-08-13 2010-10-27 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) 1-ЗАМЕЩЕННЫЕ 3-(2-ХЛОР-1Н-ИНДОЛ-3-ИЛ)-4-ФЕНИЛ-1Н-ПИРРОЛ-2,5-ДИОНЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ФОТОХИМИЧЕСКОГО ГЕНЕРИРОВАНИЯ СТАБИЛЬНЫХ ФЛУОРЕСЦИРУЮЩИХ СОЕДИНЕНИЙ И 2,8-ЗАМЕЩЕННЫЕ БЕНЗО[а]ПИРРОЛО[3,4-с]КАРБАЗОЛ-1,3-(2Н,8Н)-ДИОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ФЛУОРОФОРОВ
CN101812062A (zh) * 2010-03-31 2010-08-25 北京京卫信康医药科技发展有限公司 一种新的米诺膦酸重要中间体的制备方法
CN102443002A (zh) * 2010-10-12 2012-05-09 四川滇虹医药开发有限公司 2-(咪唑并[1，2-α]吡啶-3-基)乙酸的制备方法
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
HRP20230162T1 (hr) 2012-10-25 2023-04-14 Tetra Discovery Partners Llc Heteroarilni inhibitori enzima pde4
EP2928465B1 (de) * 2012-12-10 2020-11-18 Centogene GmbH Verwendung von maleimidderivaten zur vorbeugung und behandlung von krebs
WO2014090398A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2016049595A1 (en) * 2014-09-26 2016-03-31 Tetra Discovery Partners, LLC Heteroaryl inhibitors of pde4
CN106674079A (zh) * 2015-11-10 2017-05-17 南京卡文迪许生物工程技术有限公司 一种帕比司他的合成方法
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
EP3920885A1 (de) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen
CN113801054A (zh) * 2021-09-30 2021-12-17 西南大学 3-烷基-3-羟基吲哚-2-酮及其衍生物的制备方法及其产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
AU2576901A (en) 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1242420A2 (de) 1999-12-16 2002-09-25 Eli Lilly And Company Mittel und verfahren zur behandlung von proliferativen erkrankungen
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
BR0116468A (pt) 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
WO2003076442A1 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US7405305B2 (en) 2008-07-29
DE60315270D1 (de) 2007-09-13
MXPA04008671A (es) 2004-12-06
EP1487822A2 (de) 2004-12-22
WO2003076398A2 (en) 2003-09-18
KR20040091113A (ko) 2004-10-27
EP1487822B1 (de) 2007-08-01
AU2003217596A1 (en) 2003-09-22
CA2477984A1 (en) 2003-09-18
WO2003076398A3 (en) 2004-02-26
DE60315270T2 (de) 2008-04-17
ATE368657T1 (de) 2007-08-15
CN1639152A (zh) 2005-07-13
ES2289274T3 (es) 2008-02-01
JP2005530707A (ja) 2005-10-13
US20050288321A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
IL163777A0 (en) Kinase inhibitors
IL163781A0 (en) Purine derivatives as kinase inhibitors
PT1761520E (pt) Inibidores de quinase
IL160915A0 (en) Indolizines inhibiting kinase proteins
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
SG160211A1 (en) Pi-3 kinase inhibitor prodrugs
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
PT1442024E (pt) Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b)
TW200640924A (en) VEGF-R2 inhibitors and methods
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
PL375389A1 (en) Novel inhibitors of kinases
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
GB0308201D0 (en) Novel compounds
MY143516A (en) Kinase inhibitors
JO2242B1 (en) Phosphatase inhibitors
AU2003290592A1 (en) Antitumor benzoylsulfonamides
SE0103710D0 (sv) Compounds